Blog

Research!America is dedicated to ensuring a strong public and private sector investment in research to improve health at a level warranted by scientific opportunity and supported by public opinion. Each blog post aims to inform readers about the health and economic benefits of research.  

Recent Blog Posts

Dear Research Advocate, A refreshing number of members of Congress have allocated time during this recess to champion medical research, among them Senators Capito (R-WV), Franken (D-MN), and Kirk (R-IL), and Representatives Burgess (R-TX-26), Dold (R-IL-10), Israel (D-NY-03), Lance (R-NJ-07) and Walden (R-OR-02). Rep. Dold, for example, visited Northwestern University Feinberg School of Medicine as well as private industries in his district, like Marathon, to discuss ways to speed up medical innovation. Visiting the genetics lab at Northwestern, Rep. Dold commented: “We spent a little over 330 billion dollars this year in treating diabetes alone. Can we get some [additional] research...
Dear Research Advocate: Research!America is proud to serve as a lead sponsor of the American Association for Cancer Research (AACR) Rally for Medical Research, a two-day event in Washington, DC next month. The Rally will unite individuals from across the medical research advocacy community to push for making National Institutes of Health (NIH) funding a higher national priority. Events begin on Wednesday, September 16 with an afternoon advocacy training and an evening congressional reception. On Thursday, after a breakfast featuring remarks by House Labor-HHS-Education Appropriations Subcommittee Chairman Tom Cole (R-OK-04), nearly 200 advocates will participate in Hill meetings. Add your...
Dear Research Advocate, Throughout its 26-year history, Research!America has been fortunate to attract extraordinarily gifted and dedicated national leaders to its Board of Directors. One such leader, the Honorable Louis Stokes, passed away on Tuesday . A powerhouse lawyer, founding member of the Congressional Black Caucus, skilled appropriator, and able chair of the House Ethics Committee, Lou was also a stalwart advocate for medical research and promoted efforts to address health disparities; in so many ways, Lou created a better future for all of us. Our fight for medical progress is, and will continue to be, part of his legacy. Current board member Dr. Herb Pardes wrote a compelling...
Dear Research Advocate, Although we are 452 days away from Election Day 2016, with all the media attention right now one would be forgiven for thinking it is coming up next month! The overwhelming majority of scientists surveyed by the Science Advisory Board in advance of last Thursday’s debate said that science and research should be a topic of discussion. But as predicted by the same 90+ percent majority, science wasn’t even mentioned, underscoring the importance for scientists, patients, and all who care about research to engage candidates before the next debate. If you -- a potential voter -- don’t let candidates know you care about medical progress and science writ large, they will...
Chronic diseases are a formidable public health challenge for the U.S. with more than 50 percent of Americans living daily with one or more chronic health conditions. The impact of these illnesses can be debilitating for individuals, families and local communities. Approximately 75 cents of every dollar spent on health care in 2009 was related to chronic illnesses which totaled $1.7 trillion . The main weapon available to treat chronic diseases, such as diabetes or high blood pressure, is medications. The average number of medications prescribed per capita increased from 10.1 in 1999 to 12.7 in 2014 . In fact, one of the most effective means to improve health outcomes is to ensure...
Dear Research Advocate, Research!America is on the Hill and in the media continuing to make the case for timely action in Congress to boost medical progress. I appreciated the opportunity to discuss the 21st Century Cures Act and the Senate’s Innovation initiative in a recent issue of Roll Call . The bottom line is this: we need to keep this ball rolling. Congress has a notoriously short attention span - too many issues, not enough time - so advocates should not only be pushing for what they want to see in the Senate bill, they should be pushing to see a Senate bill ASAP. Unless you’ve managed to steer clear of all forms of media in recent days, you probably know that the first official...
This op-ed appeared online on Roll Call July 31, 2015. New technology such as CRISPR-Cas9, a genuine scientific breakthrough, is raising hope for patients with cancer, cystic fibrosis, sickle-cell anemia and other major health threats. The gene editing tool, used in precision medicine, allows changes to be introduced into the DNA of any living cell— potentially enabling repair of disease causing mutations, neutralization of disease carrying insects, and much more. This technology, developed with support from the National Institutes of Health (NIH) and National Science Foundation (NSF), is an example of the realization of the promise of innovative research funded by our federal science...
Strange bedfellows? Not when it comes to research advocacy. On Monday, former House Speaker Newt Gingrich joined Senator Elizabeth Warren (D-MA) and Representative Elijah Cummings (D-MD-07) to press for more R&D in the bioscience arena. Not every topic is one on which Senator Warren and Speaker Gingrich agree , but they found common ground in the benefits that could come from another NIH doubling. The drumbeat for medical research continues apace. The Bipartisan Policy Center (BPC) released what is sure to be an influential report this week, Advancing Medical Innovation for a Healthier America . Focused on the development phase of the discovery, development, delivery continuum, the...
Dear Research Advocate: Congress has postponed further action on patent reform. Concern over provisions in the legislation poured in from a broad coalition within the life sciences community, including universities, patient advocates, and the pharmaceutical and biotech industries. BIO’s Jim Greenwood and PhRMA’s John Castellani penned a compelling op-ed on the topic for The Hill . Now there is more work to be done as policymakers and advocates continue the conversation about reforming our nation’s patent system. Stay tuned. Momentum for a two-year extension of the R&D tax credit is building in the Senate. The Senate Finance Committee, spearheaded by Senator Orrin Hatch (R-UT), voted...
Dear Research Advocate, The “moment” for research that we’ve been experiencing on Capitol Hill is being echoed by Presidential candidates; is this perhaps the start of a wave of conversation on the campaign trail? On Tuesday, the Senate Commerce Committee, which is not the committee of jurisdiction for NIH or FDA, or intellectual property, held a hearing on these very topics. Committee Chairman and Presidential candidate Ted Cruz (R-TX) framed the hearing as an opportunity to explore strategies for speeding cures to patients. The hearing might have devolved into an “FDA regulation is bad” fest, and to be honest there was some of that, but the Senators present, along with the witnesses,...

Pages

Without research, there is no hope.
The Honorable Paul G. Rogers